Select Page

December 13, 2018 – Marlborough, Mass., and PARAMUS, N.J., – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that positive results from SEP 361-201, a pivotal Phase 2 study that evaluated the efficacy and safety of SEP-363856, a novel psychotropic agent for the treatment of patients with schizophrenia, were presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla.